Download Free Sample Report

Ambrisentantable Market, Global Outlook and Forecast 2023-2030

Ambrisentantable Market, Global Outlook and Forecast 2023-2030

  • Published on : 06 December 2023
  • Pages :72
  • Report Code:SMR-7870693

Download Report PDF Instantly

Leave This Empty:

Secure

Report overview

The global Ambrisentantable market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The USA market for Global Ambrisentantable market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The China market for Global Ambrisentantable market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The Europe market for Global Ambrisentantable market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.
This report aims to provide a comprehensive presentation of the global market for Ambrisentantable, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ambrisentantable.

This report contains market size and forecasts of Ambrisentantable in global, including the following market information:

  • Global Ambrisentantable Market Revenue, 2018-2023, 2024-2030, ($ millions)
  • Global Ambrisentantable Market Sales, 2018-2023, 2024-2030, (M Pcs)
  • Global top five Ambrisentantable companies in 2022 (%)

The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
5 mg Tablet Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Ambrisentantable include GSK, Actavis (TEVA ), Gilead Sciences, Mylan Pharmaceuticals, Sigmapharm Laboratories, Noorik BioPharma, Cipla, Cadila Healthcare and Sun Pharmaceutical Industries, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Ambrisentantable manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ambrisentantable Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (M Pcs)
Global Ambrisentantable Market Segment Percentages, by Type, 2022 (%)

  • 5 mg Tablet
  • 10 mg Tablet

Global Ambrisentantable Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (M Pcs)
Global Ambrisentantable Market Segment Percentages, by Application, 2022 (%)

  • Cirrhosis Of The Liver
  • High Blood Pressure
  • Hepatorenal Syndrome
  • Graft Function Is Delayed
  • Pulmonary Hypertension
  • Heart Failure
  • Chronic Renal Failure
  • Idiopathic Pulmonary Fibrosis
  • Other

Global Ambrisentantable Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (M Pcs)
Global Ambrisentantable Market Segment Percentages, By Region and Country, 2022 (%)

  • North America (United States, Canada, Mexico)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
  • The Middle East and Africa (Middle East, Africa)
  • South and Central America (Brazil, Argentina, Rest of SCA)

Competitor Analysis
The report also provides analysis of leading market participants including:

  • Key companies Ambrisentantable revenues in global market, 2018-2023 (Estimated), ($ millions)
  • Key companies Ambrisentantable revenues share in global market, 2022 (%)
  • Key companies Ambrisentantable sales in global market, 2018-2023 (Estimated), (M Pcs)
  • Key companies Ambrisentantable sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

  • GSK
  • Actavis (TEVA )
  • Gilead Sciences
  • Mylan Pharmaceuticals
  • Sigmapharm Laboratories
  • Noorik BioPharma
  • Cipla
  • Cadila Healthcare
  • Sun Pharmaceutical Industries
  • Hansoh Pharma
  • CTTQ
  • Zhejiang Haosen Pharmaceutical

Outline of Major Chapters:
Chapter 1: Introduces the definition of Ambrisentantable, market overview.
Chapter 2: Global Ambrisentantable market size in revenue and volume.
Chapter 3: Detailed analysis of Ambrisentantable manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ambrisentantable in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Ambrisentantable capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.